CalciMedica, Inc.
CALC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | 0.13 | 0.00 |
| FCF Yield | -53.14% | -200.97% | -280.35% | -361.73% |
| EV / EBITDA | -2.34 | -0.21 | 0.39 | 0.13 |
| Quality | ||||
| ROIC | -150.24% | -268.17% | 1,155.78% | -55.28% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.54 | 0.75 | 1.50 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 18.03% | -2.69% | 21.44% | 3.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.58 | 0.16 | 1.56 | 0.38 |
| Interest Coverage | 0.00 | -198.86 | -107.52 | -285.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -1.33 | -24.71 |
| Cash Conversion Cycle | -12,573.62 | -8,929.91 | -20,390.87 | -385.39 |